Niagen Bioscience
NAGE
58 hedge funds and large institutions have $27.7M invested in Niagen Bioscience in 2018 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 13 closing their positions.
575% more call options, than puts
Call options by funds: $452K | Put options by funds: $67K
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
9% more funds holding
Funds holding: 53 → 58 (+5)
1.63% more ownership
Funds ownership: 10.41% → 12.04% (+1.6%)
16% less capital invested
Capital invested by funds: $33.1M → $27.7M (-$5.37M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.22M |
| 2 |
Goldman Sachs
New York
|
+$1.12M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.01M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$901K |
| 5 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$652K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Precept Management
Dallas,
Texas
|
-$1.18M |
| 2 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$843K |
| 3 |
Renaissance Technologies
New York
|
-$265K |
| 4 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$257K |
| 5 |
JP Morgan Chase
New York
|
-$236K |
NAGE Hedge Fund Activity: Q1 2018 in Review
58 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q1 2018, worth a combined $27.7M — down 16% from $33.1M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new NAGE positions and 13 closed out — a net gain of 6 holders — while 13 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.22M. The largest seller was Precept Management, exiting entirely with an estimated $1.18M sold.
- 58 institutional investors held Niagen Bioscience (NAGE) as of Q1 2018, up from 53 in Q4 2017.
- Funds reported $27.7M of Niagen Bioscience stock for Q1 2018, down 16% quarter-over-quarter.
- 19 funds opened new Niagen Bioscience positions in Q1 2018 and 13 closed out, a net change of +6 holders.
- The largest Niagen Bioscience buyer in Q1 2018 was Vanguard Group, an estimated $1.22M added.
- The largest Niagen Bioscience seller in Q1 2018 was Precept Management, an estimated $1.18M sold.
Based on aggregated 13F filings for Q1 2018.